Immunochromatographic (lateral-flow) immunoassays offer a quick and easy way to detect analytes with a concentration generally greater than 1 ng/mL. Although with optimisation and careful selection of antibodies it is possible to push the detection limit lower, this technology lacks the robustness for detection of lower levels of analytes required for some clinical applications, particularly for monitoring tumour marker and cytokine levels.
We are currently exploring new technology to improve the sensitivity and reliability of low-cost, easy to use rapid diagnostics at our R&D labs in North Wales. Ultra-sensitive point-of-care diagnostics offers new opportunities for monitoring patients at home, reducing the need for routine outpatient appointments and laboratory resources.